The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISTH 2023 | Quality of life with octocog alfa in patients with hemophilia A: read-out of the AHEAD study
Kate Khair, PhD, Haemnet, London, UK, briefly discusses patient quality of life (QoL) outcomes from the interim read-out of the AHEAD study, which is evaluating octocog alfa in patients with hemophilia A (NCT02078427). This study measured QoL over time, allowing for tracking of QoL alongside treatment. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
